RxDoctor Payments Data

Arma Velasquez

Podiatrist · El Paso, TXNPI 1285632562

Payments from drug & device makers

$12,759in general payments, 2019–2025

Across 197 payments — averaging $64.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Treace Medical Concepts, Inc.$5K
  • Smith+Nephew$2K
  • Medical Device Business Services, Inc.$1K
  • Paragon 28, Inc.$1K
  • Nvision Biomedical Technologies, Inc.$636
  • Progenacare Global, LLC$584
  • plus $2K from 20 others

What the payments were for

  • Speaking & faculty fees$1371%
  • Travel & lodging$5,10840%
  • Food & beverage$7,51459%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,759 in reported general payments places this provider in the 85th percentile of 470 podiatrist providers in Texas.

See all podiatrist providers in Texas

Medicare billing

Part B allowed, 2024
$64,074
Medicare patients
180
Services billed
991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.28$16,012
CiclopiroxCiclopirox Olamine357$13,487
Ciclopirox356$12,806
Ketoconazole189$3,457
Ammonium Lactate196$3,442
Clotrimazole103$2,520
Diclofenac Sodium56$1,908
Triamcinolone Acetonide159$1,198
Methylprednisolone88$703
Gabapentin35$449
Terbinafine Hcl39$399
Cephalexin24$202
Clindamycin Hcl13$146
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim21$141
Levofloxacin17$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$1,620$16,01228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 470 podiatrist providers in Texas.

Other podiatrist in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →